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Abstract 
With the advent of novel bioorthogonal reactions and “click” chemistry, an increasing number of 
strategies for the single labelling of proteins and oligonucleotides have emerged. Whilst several 
methods exist for the site-selective introduction of a single chemical moiety, site-selective and 
bioorthogonal dual modification of biomolecules remains a challenge. The introduction of multiple 
modules enables a plethora of permutations and combinations and can generate a variety of 
bioconjuguates with many potential applications. From de novo approaches on oligomers to the post-
translational functionalisation of proteins, this review will highlight the main strategies to dually 
modify biomolecules. 
Review 
1. Introduction 
a. Bioorthogonal reactions and click chemistry on biomolecules 
The last decade has witnessed the rapid and sustained development of novel bioorthogonal reactions 
that display exquisite chemoselectivity in the presence of biomolecules. In this burgeoning chemical 
scene of site-selective functionalisation, various approaches for labelling different classes of 
biomolecules (e.g. oligonucleotides, proteins) with a single entity have been developed. The amount of 
research being conducted in this field and related areas is growing and a vast number of papers and 
reviews have been published in recent years.
1-9
  
There are two main strategies for the selective and bioorthogonal chemical labelling of 
oligonucleotides. The first consists of incorporating a nucleic acid analogue (e.g. a nucleoside 
phosphoramidite), usually under automated solid-phase synthesis conditions.
10, 11
 Importantly, this 
method is restricted to labels or chemical handles that can withstand the harsh conditions of 
oligonucleotide synthesis and deprotection.
12
 The second is post-synthetic labelling in solution, which 
allows for incorporation of labels too sensitive for the first approach.
13
 
Selectivity in the modification of proteins is also commonly achieved via two distinct approaches. 
Either the reactivity of a chemical reagent is adjusted to be selective for a single natural amino acid or 
an unnatural amino acid (uAA) is incorporated into the target protein, which offers a unique reactivity 
that is orthogonal to the surrounding groups. Thus, using these approaches, proteins can be 
manipulated at the single amino acid level to allow numerous applications both in vitro and in vivo.  
Regardless of the approach, or the class of biomolecule to be functionalised, the chemoselective 
reaction(s) required for site-selective modification often fall under the category of “click” reactions. 
Click chemistry has been defined as a set of reactions that are modular, stereospecific, wide in scope, 
high yielding, generate only inoffensive by-products, have simple reaction conditions and generate 
products that are easy to purify.
14
 Click chemistry and bioorthogonal chemistry therefore often reflect 
similar chemical principles.
15
 Indeed, click reactions generally offer water compatible chemistry and 
their potential for bioorthogonal, regioselective and high-yielding conjugation under mild conditions 
make them ideal candidates for the chemical functionalisation of biomolecules. For these reasons, 
among the numerous functionalisation strategies for biomolecules, the use of “click” chemistry has 
received particular attention. Due to its ever-growing importance, “click” chemistry on proteins and 
oligonucleotides has been reviewed extensively in the past few years, although they are mainly 
focused on the single modification of biomolecules.
15-21
 
b. Dual modification of biomolecules 
Whilst several methods exist for the site-selective introduction of a single chemical moiety, site-
selective and bioorthogonal dual modification remains a challenge. One early method used to 
incorporate two functionalities into biomolecules is the de novo total synthesis of oligomers, though 
this method is still suboptimal. Whilst bis-heterolabelled oligonucleotides could be prepared 
successfully,
12,22-24
 this approach was not amenable to long peptides and full-length proteins and, 
despite recent developments in this field, remains limited to short fragments.
25, 26
  
c. Multifunctional scaffolds – Applications  
The use of dual modification is essential for certain applications that require at least two functional 
groups to be introduced into a protein, e.g. Förster resonance energy transfer (FRET),
27
 experiments 
for folding studies,
28
 targeted theranostic biopharmaceuticals,
29-31
 or protein–drug therapeutics 
stabilised with conjugated half-life extension chemistry.
31,32
 Furthermore, attachment of fluorescent 
probes or affinity tags to oligonucleotides is critical to research in nanotechnology and modern life 
sciences.
22, 33, 34
 For example, site-specific functionalisation with two or more distinct FRET pairs 
allows for the development of oligonucleotide probes for imaging purposes.
35, 36
 These systems attract 
high interest since they are essential for techniques such as flow cytometry,
37
 real-time polymerase 
chain reaction,
38
 and advanced fluorescence microscopy.
39
 Indeed, multifunctional scaffolds have a 
myriad of uses and can find significant utility in a wide range of areas. It is therefore crucial to 
develop more straightforward, practical and versatile methods for the introduction of two modalities 
into biomolecules.  
The aim of this review is to give an overview of the current existing strategies for the dual 
modification of DNA, RNA and proteins. As recent research has shown a clear shift towards site-
selective methodologies, these approaches will be given particular emphasis. We hope this review will 
allow the reader to grasp the main strategies and uses of this emerging yet rapidly expanding field. 
2. Dual modification of oligonucleotides 
Due to their remarkable efficiency, “click” reactions, in particular the CuI-catalysed [3+2] alkyne–
azide cycloaddition (CuAAC), have enabled a plethora of novel ideas and applications to be readily 
appraised in the nucleic acid field.
21
 It is well documented that, in addition to the high efficiency of 
these reactions and the mild conditions required, alkynes and azides can be incorporated into 
oligomers without greatly affecting their biophysical properties. 
a. DNA 
i. Sequential approaches 
Gramlich et al. were the first to report a CuAAC-based method for the multiple, sequential labelling of 
small DNAs.
12
 By using orthogonal protection/deprotection strategies with alkyne-bearing nucleotides 
capped with trimethylsilyl and triisopropylsilyl groups, highly efficient and sequential conjugations of 
a variety of azide-containing molecules (e.g. sugars, fluorophores) were demonstrated (Scheme 1).  
 
Scheme 1: Protection/deprotection strategy for DNA dual modification. 
Interestingly, this triple click strategy was shown to be amenable both on solid support and in solution 
with variable efficiency, and the labels could also be introduced outside the nucleobases by using 
alkyne-bearing non-nucleoside DNA modifiers. 
Another approach to dually modify DNA is to first incorporate a “clickable” nucleotide, then pause the 
elongation of the chain to react it, add a second reactive nucleotide and continue elongation before 
reacting the second reactive nucleotide; thus avoiding the need for additional protection/deprotection 
steps. The first functionalisation can occur during automated oligonucleotide synthesis and the second 
can either take place on solid support or post synthesis in solution to allow for the incorporation of 
more sensitive labels.
22, 23
 
Using this approach, Astakhova et al. optimised CuAAC conditions and developed a strategy for 
internal labelling of DNA by combining solid-phase and postsynthetic CuAAC reactions (Scheme 2).
22
  
 Scheme 2: Sequential double CuAAC on oligonucleotide with elongation interruption. 
This method was exemplified through the preparation of novel fluorescent probes containing a variety 
of fluorophores in moderate to excellent yields. The main challenge of this strategy was the 
incompatibility of oligonucleotide synthesis with the aqueous conditions required for CuAAC which 
resulted in additional washing and drying steps. 
Alternatively, instead of interrupting the elongation at each step of incorporation of a chemical handle 
(e.g. alkyne), Pourceau et al. showed that azide functions could be incorporated post-synthetically on a 
DNA that possessed reacted alkynes and pendant alkyl bromides, thus allowing for specific and 
sequential dual modification. Using an alkyne-bearing and a bromohexyl-bearing phosphoramidite 
derivative as a precursor to azide functionalisation, a series of glyco oligonucleotide conjugates were 
successfully prepared (Scheme 3).
23
 The carbohydrates could be introduced either at the 3’- or 5’-end 
of oligonucleotides using microwave-assisted CuAAC in high conversion and moderate isolated 
yields. Interestingly, reactions on solid support and in solution were compared and led to similar purity 
profiles and isolated yields. The use of bromohexyl as a precursor to azide functionalisation was 
necessary as azides can react with P
III 
via a Staudinger reaction during phosphoramidite-based 
oligonucleotide synthesis.
40
 
 
Scheme 3: Sequential double CuAAC on DNA with post-synthetic azidation. 
ii. One pot modification 
In an attempt to simplify the procedure for the dual modification of DNA, it was demonstrated that 
two orthogonal functional groups can also be added to the oligonucleotide which can then be 
simultaneously dual-modified. Indeed, by combining CuAAC click reaction and inverse electron-
demand Diels−Alder reaction36, or strain-promoted azide–alkyne [3+2] cycloaddition (SPAAC) and 
NHS ester coupling
41
, oligonucleotide FRET probes could be prepared in a one-pot, site specific and 
high yielding process. 
b. RNA 
Pradère et al. adapted a solid phase synthesis-based method for double hetero-labelling of DNA to 
long pre-microRNAs.
22
 In this approach, a single alkyne-modified nucleoside is attached and the 
synthesis is interrupted to allow for selective reaction of this first reactive handle. Synthesis is 
subsequently resumed and the second alkyne-modified nucleoside is attached and reacted with a 
second label (Scheme 2).
24
 Although this afforded the desired modified RNAs, incomplete CuAAC 
resulted in cross-labelling, affording complex mixtures which proved inseparable in some cases. 
Santner et al. described a method to synthesise siRNA with a 3’ terminal azide and a primary amine 
using phosphoramidite nucleoside. These two handles can be sequentially reacted with an alkyne and 
an activated acid respectively to enable access to hetero bifunctional RNA.
42
Although this approach 
alleviates undesirable cross-labelling, the use of the azido-modified nucleoside is restricted to the 3’-
end of RNA due to the incompatibility of azides and the phosphoramidite method.
40
 However, taking 
inspiration from a method for bis-heterolabelling of short DNA that uses an alkyne- and a bromide-
bearing phosphoramidite
23, Pradère et al. recently developed a method for double hetero-labelling of 
pre-microRNAs that circumvents this restriction.
43
 By incorporating and reacting an alkyne and a 
bromide-bearing nucleoside sequentially, a series of dually modified pre-microRNAs labelled at 
various positions were prepared in high purity (Scheme 4). The prepared oligonucleotides bearing 
fluorescent dyes and forming a fluorescence resonance energy transfer pair were then used as probes 
for miRNA maturation in an in vitro assay. 
 
Scheme 4: Bis-heterolabelling of pre-miRNA. 
3. Dual modification of peptides and proteins 
The main approaches to dually modify peptides and proteins can be classified in two separate 
categories (Figure 1).
44
 The first one is the modification of two amino acids on the proteins using 
various methods that include: exploiting the difference of accessibility or reactivity of amino acids,
45-47
 
functionalisation of the C- and N-terminus of proteins,
48
 use of unnatural amino acids,
49-51
 use of 
specific enzymes
50
 or a combination of these strategies
52
. The second category involves conjugation of 
a multifunctional linker to the protein of interest. The multifunctional scaffold can then be reacted to 
give a dually modified conjugate.
19, 31, 44, 53
 
 
Figure 1: Different approaches for the introduction of two functional moieties to a protein. (a) Via two 
amino acids; (b) Via a multifunctional scaffold containing the two reactive handles. 
a. Approach using two amino acids 
i. Native amino acids 
1. Identical amino acids with different reactivity 
By exploiting the difference of accessibility or reactivity of two identical amino acids, it is possible to 
site selectively dual-modify proteins. To demonstrate the feasibility of this approach, Ratner et al. 
engineered a dual cysteine mutant of Escherichia coli adenylate kinase and, by carefully selecting the 
position of the engineered cysteines, the reaction times and the stoichiometry of reagents, the authors 
could generate doubly labelled proteins.
45
 This method relies on sufficient difference in reactivity of 
the cysteines so that the most reactive cysteine can be selectively reacted by addition of a weakly thiol-
reactive reagent, and the less reactive cysteine subsequently modified with a highly thiol-reactive 
reagent. After purification of the mixture obtained, the resulting conjugates were isolated in ca. 70% 
yield and were further used for spectroscopic studies of protein folding and dynamics. 
Although this is a powerful and useful concept, it heavily relies on identifying cysteines with suitable 
differences in reactivity, which is not straightforward or easily predicted. A reaction with moderate 
selectivity would lead to heterogeneous mixture of products and would require intermediate 
purification steps. 
Nevertheless, using a similar approach and through identification of cysteine environments with 
significant differences in nucleophilicity, Moody et al. engineered cysteine mutants of designed 
ankyrin repeat proteins (DARPins) that can be sequentially and quantitatively modified with 
appropriate thiol-reactive reagents.
47
 Due to the high selectivity of the reactions, their method for the 
dual modification of DARPins allowed for clean and high-yielding sequential functionalisation 
without the need for intermediate purification (Scheme 5). 
 
Scheme 5: Dual modification of DARPins 
Recently, Zhang et al. showed that a four-amino-acid sequence (Phe-Cys-Pro-Phe), called the 
“π-clamp” tunes the reactivity of its cysteine thiol for site-selective conjugation with 
perfluoroaromatic reagents.
54
 The “π-clamp” strategy was exemplified on a fusion protein of the 
anthrax toxin lethal factor 1–263 and diphtheria toxin domain A with an engineered N-terminal 
cysteine and a C-terminal π-clamp. Using a one-pot procedure, the protein was successfully dually 
modified with a small peptide and a fluorophore in a site-selective manner (Scheme 6).  
 
Scheme 6: Dual modification by π-clamp approach. 
The aforementioned strategies require protein engineering to incorporate cysteines at specific positions 
which can lead to complications during expression or functionalisation (e.g. aggregation, 
scrambling).
55
 
The approaches described above for protein modification rely on the nucleophilicity of the target 
residue. Selectivity is achieved almost exclusively by using protein modification reagents carefully 
designed to exploit the differences in reactivity of the amino acid side chains under carefully 
controlled conditions.  
Taking a different approach, Nathani et al. showed that the outcome of a reaction between cysteine 
residues and a single reagent (i.e. 2,5-dibromohexanediamide) could be controlled using only the local 
protein microenvironment.
46
 This site-selective dual functionalisation of a protein based on substrate 
control was exemplified on a double cysteine mutant of superfolder green fluorescent protein.  
The protein was initially transformed into a bis-sulfonium through reaction with 
2,5-dibromohexanediamide. Depending on the protein microenvironment, the sulfonium either 
persisted as a stable entity or eliminated to yield dehydroalanine. These functional groups were 
subsequently reacted independently to yield a site-selective dually modified protein (Scheme 7). 
 
Scheme 7: Dual modification by substrate control using 2,5-dibromohexanediamide. 
2. Identical amino acids sequentially 
Instead of taking advantage of the differential reactivity of cysteine residues, it is also possible to 
independently prepare two functionalisable fragments of a protein, modify them independently and 
then join them together to generate the dually modified biomolecule. This can be achieved using 
expressed protein ligation (EPL) either on solid support
56
 or in solution
48, 57
. 
De Rosa et al. described a homogeneous dual-labelling strategy where EPL, a method related to native 
chemical ligation which expands its applicability to recombinant protein fragments, was exploited.
57
 A 
cysteine-containing N-terminal fragment of a protein was first generated and it was reacted with a 
probe. The second C-terminal fragment was then attached using EPL and finally modified with a 
second cysteine-reactive probe. This strategy was also applied to a full length protein by replacing the 
second fragment by a cysteine (Scheme 8). This method was exemplified with a series of repeat 
protein CTPR3 (Consensus TetratricoPeptideRepeat) functionalised with fluorophore pairs at different 
positions in the protein.  
 Scheme 8: Dual labelling of proteins using EPL. 
Yang et al. reported an alternative approach to cysteine labelling of fragments to afford a dual-labelled 
di-ubiquitin structure, thus facilitating FRET studies.
58
 The approach relied upon generating protein 
fragments that contained a single cysteine for fluorophore conjugation, labelling each individual 
cysteine, and joining the fragments to generate a full-length protein through split intein-mediated 
protein splicing. Inteins are peptide sequences that mediate self-splicing when inserted within a larger 
precursor polypeptide. They are eliminated from the precursor sequence as they facilitate conjugation 
of the N- and C-terminal regions into a new protein.
59
 
Both EPL and protein splicing are powerful methods that have allowed studies in areas such as 
electrophysiology for the monitoring of ion channels,
60
 NMR through the introduction of specific 
isotopes,
61
 and optical spectroscopy;
62, 63
 all with the aim of probing protein structure and function. 
Interestingly, both approaches could potentially be adapted to the introduction of more than two 
molecular probes. 
Enzymatic approaches for the dual modification of proteins have also been developed.
48
 These 
methods generally use sortases that catalyse transpeptidation reactions.
64
 Target proteins are 
engineered to have, at both ends, the recognition sites necessary for each enzyme. In the presence of a 
labelled peptide, the transpeptidation reaction can then take place. 
By exploiting the orthogonality of two sortase enzymes with unique reactivities (i.e. sortase A from 
Staphylococcus aureus, SrtAstaph, and sortase A from Streptococcus pyogenes, SrtAstrep), Antos et al. 
developed a strategy for placing different chemical labels at the two termini of a protein. The approach 
consists of installing the first modification on the C-terminus using SrtAstrep, which results in the 
formation of a peptide sequence that cannot be cleaved by SrtAstaph. Following deprotection of the N-
terminus of the protein using thrombin, the liberated glycine residue can then be coupled using 
SrtAstaph without disrupting the C-terminal modification, thus yielding a dually modified protein 
(Scheme 9). 
 
Scheme 9: Dual labelling of proteins using orthogonal enzymes. 
This strategy was exemplified on an eGFP mutant with five N-terminal glycines and ubiquitin 
carboxyl-terminal hydrolase isozyme L3 containing an N-terminal glycine. As a proof of concept, both 
proteins were modified in high yield and purity with two distinct fluorophores. Nevertheless, although 
highly specific, this approach is limited to the labelling of the terminal protein region. 
3. Different amino acids 
In recent years, numerous methods for the site-selective modification of antibodies have been 
developed.
65, 66
 By selecting two orthogonal reactions in this ever-increasing pool, Puthenveetil et al. 
generated dual-labelled, site-specific antibody and antibody–fragment conjugates.  
This approached was demonstrated on a cysteine mutant of trastuzumab. The first reactive handle was 
installed by enzymatic conjugation using transglutaminase to couple a strained alkyne to the 
deglycosylated antibody. Following this, using a careful reduction/re-oxidation strategy allowed for 
the reaction of the liberated engineered cysteine to a maleimide-modified fluorophore. In a last step, 
the strained alkyne installed in the first step was reacted with a suitable cyanine-based dye to generate 
the dually functionalised antibody in a homogeneous and site-selective manner (Scheme 10).
52
 
 
Scheme 10: Dual labelling of proteins by combining orthogonal methods. A. Deglycosylation; B. 
Enzymatic conjugation; C. Reduction/re-oxidation; D. Michael addition/SPAAC. 
Although this method requires several steps, it is virtually compatible with all IgG1s as the 
incorporation of non-canonical cysteine has been shown to be compatible across antibodies and they 
all share the same glycosylation site.
67
 
ii. Non-canonical amino acids 
Dual functionalisation of biomolecules can be achieved by targeting different unnatural amino acids 
with orthogonal reactivity. The insertion of two uAAs in proteins is dependent on the availability of 
unnatural protein expression methods to incorporate orthogonal chemical handles for subsequent 
bioorthogonal reactions.
5, 68, 69
 A common strategy to introduce two mutually orthogonal chemical 
handles is to combine nonsense and quadruplet codon suppressions.
70-73
 
Neumann et al. have reported the incorporation of two uAAs into a protein by synthetically evolving 
an orthogonal ribosome that efficiently decodes a series of quadruplet codons and the amber codon, 
providing several blank codons on an orthogonal mRNA, which it specifically translates. The authors 
created mutually orthogonal aminoacyl-tRNA synthetase–tRNA pairs and combined them with ribo-
Q1 to effect incorporation of two uAAs into the protein sequence. At the same time, Wan et al. 
independently developed another method to introduce two non-natural amino acids in the same protein 
by using two stop codons, amber codon UAG and ochre codon UAA.
71
 This method was used to 
incorporate two fluorophores for FRET analysis of glutamate binding protein (QBP) and superfolder 
green fluorescent protein (GFP). 
Although recombinant expression strains have been engineered to improve incorporation efficiency, 
this dual-labelling approach is often associated with low protein yields.
74-76
 The main reasons for these 
low yields are the competition of uAA incorporation with translational frame shifting or termination 
and low catalytic efficiency of the engineered aminoacyl-tRNA synthetases.
77
 Thus, strategies often 
comprise unnatural protein expression in conjunction with the modification of canonical amino acids 
(e.g. cysteine). 
In 2007 and 2008, van Kasteren et al. and Brustad et al. paved the way for the development of dual-
modification of proteins bearing a single non-canoncial amino acid by successfully installing two 
distinct moieties in proteins using a combination of an uAA and cysteine. Van Kasteren et al. 
functionalised β-glycosidase from archaeon Sulfolobus solfataricus using a combination of uAA and 
cysteine modification. These handles were reacted further using sequential CuAAC and disulfide bond 
formation, respectively, to effectively mimic post-translational modifications.
78
 This uAA/cysteine 
pair was also used by Brustad et al. to incorporate ketone-containing uAAs (i.e. p-
acetylphenylalanine) and cysteines in a T4 lysozyme to generate mutants for the study of T4 lysozyme 
folding at single-molecule resolution by FRET using oxime ligation and Michael addition, 
respectively.
79
 
 
More recently, Simon et al. reported a dual-labelling approach for DARPins using a combination of 
uAA and cysteine functionalisation.
51
 Azidohomoalanine was introduced at the N-terminus of the 
protein and a cysteine was introduced at a second position of interest via site-directed mutagenesis. 
SPAAC reaction was utilised for orthogonal functionalisation of azidohomoalanine, followed by 
maleimide modification of the single cysteine residue to obtain homogeneous dually functionalised 
DARPin (Scheme 11). 
 
Scheme 11: DARPin dual functionalisation using SPAAC followed by thiol modification. 
To alleviate some issues associated with the incorporation and reaction of cysteines (e.g. disulfide 
bond formation, reaction reversibility, side-reactions), Mühlberg et al. recently described a dual-
labelling strategy for proteins that combines residue-specific incorporation of uAA with chemical 
oxidative aldehyde formation at the N-terminus of a protein.
49
 The authors selectively introduced two 
different functional moieties in thermophilic lipase from Thermoanaerobacter thermohydrosulfuricus 
via CuAAC and oxime ligation (Scheme 12). This method was applied to the conjugation of biotin and 
β-linked galactose residues to yield an enzymatically active thermophilic lipase. 
  
 Scheme 12: Lipase dual functionalisation using oxime ligation followed by CuAAC modification. 
By engineering both azidohomoalanine and a pentapeptide that can be utilised for sortase A-mediated 
ligation (SML) at the C-terminus of a truncated thrombomodulin domain, Jiang et al. could combine 
SPAAC and SML to generate dual-modified proteins.
50
 After optimisation of the reaction conditions, 
the protein of interest was functionalised with a PEG chain and a fluorophore in a one-pot/site-specific 
process without disrupting the activity of the recombinant thrombomodulin.  
A similar approach that combines an uAA and a peptide sequence was also developed by Grünewald 
et al.
80
 A pyrroline-carboxy-lysine and a dodecameric S6 peptide were engineered in various protein 
scaffolds and dually tagged proteins were site-selectively prepared using 2-aminobenzaldehyde-
activated fluorophores and phosphopantetheinyl transferase-catalysed reaction in a one-pot process. 
b. Approach using a multifunctional scaffold containing two reactive handles 
If the two labels are not required to be on different amino acids, a more straightforward approach to 
achieve dual modifications on proteins is to combine the reactive handles onto a single multifunctional 
scaffold incorporated into the protein or that could be conjugated to proteins.
19
 The multifunctional tag 
can either contain the two desired labels
81
 or can be subsequently chemoselectively modified with the 
desired labels.  
i. Endogenous multifunctional scaffold 
As an alternative to the simultaneous incorporation of two unnatural amino acids, a single, well-
designed uAA that possesses two orthogonal handles can also be used for direct dual functionalisation 
of proteins. To this effect, Yamaguchi et al. recently designed a N
ε
- benzyloxycarbonyl-L-lysine 
derivative with both amino and azido groups in the benzyl moiety.
82
 The phenylazide could undergo 
either alkyne−azide cycloaddition or a photo-induced reaction, while the phenylamine can undergo 
selective reductive alkylation under specific conditions. As a proof of concept, the bifunctional uAA 
was incorporated into the variable domain of a camelid heavy-chain antibody without affecting its 
binding properties. The resulting protein was subjected to an aldehyde linked to a 5 kDa polyethylene 
glycol and an azadibenzocyclooctyne linked to a fluorophore in a one-pot procedure (Scheme 13). 
After purification, the site-specific, dually modified conjugate was isolated in ca. 80% yield. 
 
Scheme 13: Dual modification of protein using bifunctional uAA. 
ii. Exogenous multifunctional scaffold 
Although there are many available scaffolds that contain bifunctional linkers, there are relatively few 
that possess three orthogonal handles, thus enabling attachment to a protein followed by dual 
modification.
19
 Efforts have been made towards the development of such platforms but with limited 
success, due to the potentially complex synthesis of a branched structure with orthogonal handles.
83, 84
 
Furthermore, these platforms have often been exemplified on small molecules or short peptides but 
rarely on proteins, which can represent an additional layer of difficulty.
85, 86
  
For example, trifunctional scaffold 1 was reacted with three small molecules (i.e. drug and 
fluorophores) and, clickable decapeptide scaffold 2 was attached to a glucose derivative and two short 
peptides, but no reaction was reported on proteins (Figure 2). 
 Figure 2: Multifunctional platforms with the potential to enable the dual functionalisation of proteins. 
Rashidian et al. described a method to site-specifically prenylate proteins containing a C-terminal 
“CaaX-box” amino acid sequence (i.e. a sequence where “C” represents a cysteine, “a” an aliphatic 
amino acid and “X” can be M, S, Q, A or C) with various isoprenoids using Protein Farnesyl 
Transferase (PFTase). A triorthogonal reagent was synthesised to allow incorporation of an alkyne and 
an aldehyde group simultaneously into a protein.
53
 
To illustrate the capabilities of this approach, a model protein (i.e. GFP) and a therapeutically useful 
protein (i.e. ciliary neurotrophic factor) with engineered CaaX-box were enzymatically modified with 
a synthesised triorthogonal reagent that allowed incorporation of an alkyne and an aldehyde group 
simultaneously into the protein. Using both oxime ligation and CuAAC reaction to incorporate a series 
of “clickable” molecules, the authors successfully generated a series of dually modified conjugates in a 
one-pot procedure (Scheme 14).  
Scheme 14: Dual modification using triorthogonal prenylation reagent.  
Beal et al. also developed a heterotrifunctional template that utilises click reactions (both copper-free 
and copper-mediated) to effect non-enzymatic sequential biomolecule conjugations in a one-pot 
process. Following the preparation of substrate 3, SPAAC followed by CuAAC was used to react its 
two alkynes handles and give dually modified template 5 which was purified by HPLC. Finally, 5 was 
reacted with a maleimide-functionalised BSA modified via its lysines with an average of 15 – 25 
maleimides per protein to yield heterogeneous dually modified BSA 6 (Scheme 15). The scope of 
compatible substrates was illustrated through conjugation of peptide, sugar, lipid, fluoroalkane, biotin 
and fluorophore molecules.
84
 
 
Scheme 15: Dual modification using heterotrifunctional template 3.  
Temming et al. described a dual-functionalisation method where the two handles were introduced 
directly by modifying a serine residue on the N-terminus of a peptide (i.e. cell-penetrating peptide 
human lactoferrin) or on proteins (i.e. enhanced GFP mutant and heat shock protein HspB2).
44
 The 
authors rationalised that this approach potentially alleviates the need for lengthy syntheses of complex 
platforms used in exogeneous modification strategies. The methods consists of a careful oxidation of 
the requisite N-terminal serine residue 7 with NaIO4 as the oxidising agent followed by reaction of the 
resulting aldehyde 8 with a large excess of N-propargylhydroxylamine to yield dually “clickable” 
protein 9. 
Following this, the first functional label was introduced by strain-promoted alkyne–nitrone 
cycloaddition (SPANC) with a “clickable” BCN-biotin derivative. The terminal acetylene of 10 then 
served as the second anchor point for a CuAAC reaction with azido-containing fluorescein to give 
dually modified construct 11 (Scheme 16).  
 
Scheme 16: Dual modification of GFP mutant using terminal serine modification.  
At the same time, Munch et al. reported a similar site-selective three-component reaction for dual-
functionalisation of peptides and proteins using a maleimide as the dipolarophile in the nitrone/alkene 
cycloaddition.
87
 
Recently, Wang et al. reported a pH-dependent method for the site-selective dual modification of 
cysteine-containing proteins and peptides based on water-soluble allyl sulfone trifunctional reagent 
12.
88
 As allyl sulfones can undergo one Michael reaction with thiols at pH 6 and, after elimination, a 
second one at pH 8 in a sequential fashion, bis-labelled allyl-sulfone 13 was prepared and successfully 
added to a recombinant cysteine-containing GFP (Scheme 17).  
 
Scheme 17: Dual modification using water-soluble allyl sulfone trifunctional reagent.  
Recently, Chudasama et al. reported that reagents based on pyridazinedione (PD) could be used as a 
platform to dually modify cysteine-containing biomolecules.
31, 89-92
 Indeed, in addition to the two 
cysteine-reactive centres, these compounds possess two additional points of attachment that can be 
functionalised. To this end, Maruani et al. prepared a series of PD-based platforms with orthogonal 
handles (e.g. strained alkyne, alkyne) that could easily be reacted with cysteines via Michael 
addition.
31, 93
 By the introduction of PD molecules bearing orthogonal “clickable” handles into the 
native disulfide bonds of an antibody and antibody fragment (i.e. trastuzumab and Fab fragment from 
trastuzumab), the authors generated a range of site-selectively dually-modified bioconjugates using 
two sequential click reactions (Scheme 18). 
 
Scheme 18: Dual modification of disulfide-containing proteins using PDs.  
The prepared conjugates bearing a drug and a fluorophore, or a drug and a half-life extension modality 
were assayed in vitro and demonstrated retention of both activity and stability. 
4. Conclusion and outlook 
In conclusion, a plethora of methods for the dual (and even tri-) modification of biomolecules in a 
selective manner has been developed, especially in recent years. However, further 
sophisticated/tailored strategies are required to overcome the remaining limitations of existing 
methodologies. Indeed, many challenges still remain; these include the stability and solubility of 
protein-expressed fragments, the harsh reaction conditions used in oligonucleotide synthesis, partial 
conversions or low yields, incomplete bioorthogonality, the lengthy syntheses of heterofunctional 
scaffolds and slow rates of reaction. 
Even with further novel technologies ironing out these issues, it is our belief that it is unlikely that one 
particular method will prevail for the dual modification of proteins or oligomers. Instead it is 
envisaged that a general set of rules based on the accrued knowledge of the use of each platform will 
allow us to determine what is the most appropriate method to at least dually modify a certain 
biomolecule to enable a particular application. Thus these new technologies have a key role to play in 
this process whilst concurrently providing access to multi-functionalised conjugates for applications 
that were previously thought of as unobtainable. 
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